Results 141 to 150 of about 3,657,795 (294)
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis +22 more
wiley +1 more source
Attitudes, needs, and opportunities for training on musculoskeletal disorder risk reduction in masonry. [PDF]
McFarland TC +3 more
europepmc +1 more source
Objective Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped because of side effects in the joints. Knowledge about the biologic effects of NGF on joint tissues is limited. Therefore, we explored the effects
Alia M. Obeidat +14 more
wiley +1 more source
Evaluation of health behaviors and Type D personality traits among physiotherapy students in relation to musculoskeletal disorder symptoms. [PDF]
Gębska M +5 more
europepmc +1 more source
Therapy for musculoskeletal disorders
openaire +3 more sources
T cells, the Next Big Target in Axial Spondyloarthritis?
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
Empowering community volunteers improves the well-being of family caregivers of musculoskeletal disorder patients: a randomized controlled trial. [PDF]
Sun J, Xue J, Li X.
europepmc +1 more source
The risk of an incident hospital contact with a musculoskeletal disorder in Danish occupational fishers: a register-based study. [PDF]
Remmen LN +4 more
europepmc +1 more source
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source

